Showing 3951-3960 of 4165 results for "".
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- EyeCare Associates of East Texas Announces Partnership With Private Equity Firm EyeCare Partnershttps://modernod.com/news/eyecare-associates-of-east-texas-announces-partnership-with-private-equity-firm-eyecare-partners/2478721/Brown Gibbons Lang & Company (BGL) has announced a new partnership between EyeCare Associates of East Texas (ECA) and EyeCare Partners (ECP) resulting in the addition of ECA’s four Texas clinics to ECP’s national ne
- AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DMEhttps://modernod.com/news/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/2478717/AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME). “Dosing the first patient with AXT107 shortly after the acceptance of its IND is a si
- EyeGate Pharma Announces Acquisition of Panoptes Pharmahttps://modernod.com/news/eyegate-pharma-announces-acquisition-of-panoptes-pharma/2478685/EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. EyeGate Pharmaceuticals will pay up to $4
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/Azura Ophthalmics announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significan
- Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitishttps://modernod.com/news/nicox-initiates-phase-2b-trial-of-ncx-4251-a-potential-first-in-class-treatment-for-blepharitis/2478662/Nicox SA announced the initiation of the Mississippi trial, a phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystal
- GenSight Biologics Announces Publication of Results from Lumevoq REVERSE Pivotal Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-3-trial/2478644/GenSight Biologics announced that the journal Science Translational Medicine has published results from the REVERSE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects along with key results from a non-human primate stu
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2478638/Aldeyra Therapeutics announced enrollment of the first patient in the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multicenter randomized, double-masked, parallel design, vehicle-controlled clinical trial will assess the effica
- Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASolhttps://modernod.com/news/novaliq-announces-first-patient-randomized-in-the-phase-3-trial-essence-2-of-dry-eye-treatment-cyclasol/2478637/Novaliq announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial. “The initiation of this second registrational trial represents a key milestone for b
- ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapyhttps://modernod.com/news/vigeneron-and-wuxi-advanced-therapies-enter-strategic-manufacturing-partnership-for-next-generation-ophthalmic-gene-therapy/2478606/ViGeneron and WuXi Advanced Therapies announced a partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s gene therapy pipeline addresses ophthalmic diseases with high unmet medical needs. Its lead pro